Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2021-08-31 Regulatory Filings
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
BioPorto Successfully Completes Interim Analysis of Data from Pivotal Study of NGAL in Pediatrics with Encouraging Results
Regulatory Filings Classification · 95% confidence The document is a corporate announcement regarding the interim results of a clinical trial for BioPorto's NGAL test. It provides an update on clinical progress, FDA submission plans, and explicitly states that these findings do not change the company's financial guidance. Since it is a general corporate announcement regarding business operations and regulatory progress that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2021-08-31 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a press release dated August 31, 2021, announcing the successful completion of an interim analysis of a pivotal clinical study (NGAL Test for AKI) and its implications for an upcoming FDA submission. It mentions that the findings do not alter the financial guidance provided in the 'Interim Report for Second Quarter 2021'. The text is a news announcement about clinical progress and regulatory strategy, not the full financial report (10-K or IR), a transcript (CT), or a formal proxy/voting document. Since it is a general announcement of corporate news that doesn't fit the highly specific categories like ER (Earnings Release, which focuses on financial results), DIV, or CAP, it falls best under the general regulatory/news announcement category, RNS, as it is a formal announcement released to the public/exchanges.
2021-08-31 English
BioPorto Announces Q2 2021 Report
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report' for the first half of 2021 for BioPorto Group. It contains comprehensive financial statements, management reviews, and financial highlights for the specified period. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis. Therefore, it fits the definition of an Interim/Quarterly Report. H1 2021
2021-08-18 English
Earnings Release 2021
Earnings Release Classification · 100% confidence The document is titled 'BioPorto Announces Q2 2021 Report' and contains key financial highlights, operational updates, guidance maintenance, and commentary specifically for the second quarter (Q2 2021). This structure strongly indicates an Earnings Release (ER) or an Interim Report (IR). Since it provides the key highlights and management commentary immediately upon release, it fits the definition of an Earnings Release (ER). Although it mentions an 'Interim Report for the second quarter of 2021' in the context of an investor meeting, the document itself is the initial announcement of those results, making ER the most precise fit for this summary announcement format. The length (5687 chars) is substantial enough to be the release itself, not just a brief RPA. H1 2021
2021-08-18 English
Pipeline Update Regarding COVID-19 test
Regulatory Filings Classification · 95% confidence The document is a short announcement (under 3,000 characters) regarding a pipeline update for a COVID-19 test. It provides a status update on clinical development and explicitly includes a link to an 'Attachment' (Announcement no. 13). Per the 'Menu vs Meal' rule, since this is a short announcement regarding a specific corporate update and points to an attachment, it is classified as a Report Publication Announcement (RPA).
2021-06-29 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a short announcement (2227 characters) dated June 29, 2021, providing an update on the development progress of a COVID-19 test, including timelines for data collection (Q3 2021) and potential future filings (CE mark, EUA). It explicitly states that the content does not alter the financial guidance provided in the 'Interim Report for First Quarter 2021'. This is a specific operational/pipeline update, not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific operational update that doesn't fit the other specialized categories (like DIRS, DIV, CAP, etc.), and it is an announcement rather than a full report, the most appropriate classification is the general Regulatory Filings category (RNS), as it serves as a broad regulatory disclosure regarding business operations and future plans.
2021-06-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.